Abstract
Background Liothyronine (LT3) has been increasingly used in combination with levothyroxine (LT4) in the treatment of hypothyroidism. A metal coordinated form of LT3, known as poly-zinc-liothyronine (PZL), avoided in rats the typical T3 peak seen after oral administration of LT3.
Objectives To evaluate in healthy volunteers (i) the pharmacokinetics of PZL-derived T3 after a single dose, (ii) the pharmacodynamics of PZL-derived T3, (iii) monitoring for the adverse events; (iv) exploratory analysis of the sleep patterns after LT3, PZL or placebo administration.
Methods 12 healthy volunteers 18 to 50 years of age were recruited for a Phase 1, double-blind, randomized, single-dose placebo-controlled, cross-over study to compare PZL against LT3 or placebo. Subjects were admitted three separate times to receive a randomly assigned capsule containing placebo, 50-mcg LT3, or 50-mcg-PZL, and were observed for 48h. A 2-week washout period separated each admission.
Results LT3-derived serum T3 levels exhibited the expected profile, with a Tmax at 2h and return to basal levels by 24-36h. PZL-derived serum T3 levels exhibited a ∼30% lower Cmax that was 1 h delayed and extended into a plateau that lasted up to 6h. This was followed by a lower but much longer plateau; by 24 hours serum T3 levels still exceeded ½ of Cmax. TSH levels were similarly reduced indistinguishably in both groups.
Conclusion PZL possesses the necessary properties to achieve a much improved T3 pharma-cokinetic. Drug product development of PZL should improve the delivery of T3 even further. PZL is on track to provide hypothyroid patients with stable levels of serum T3.
Competing Interest Statement
AB is a consultant for Synhtonics, Allergan, Abbvie and BLA Technology.
Clinical Trial
This is Phase-I clinical trial; registration at ClinicalTrials.gov is not mandatory. The trial was conducted under the Food and Drug Administration (FDA) exploratory investigational new drug (IND) application (IND-137796).
Funding Statement
Funded by an SBIR grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK; 5R44DK116396).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The trial was approved by the University of Chicago IRB and Clinical Research Center committees (IRB20-1341).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
EH ehanlon{at}bsd.uchicago.edu
MA Marilyn.Arosemena{at}uchospitals.edu
OD Olha.Duchon{at}uchospitals.edu
ME Matthew.Ettleson{at}uchospitals.edu
MG giurcanu{at}uchicago.edu
Data Availability
All relevant data are contained in the manuscript.
